4th carcinogen detected in common heart drug

Valisure, an online pharmacy licensed in 37 states, told the FDA it found another cancer-causing chemical in valsartan, a widely prescribed heart drug, according to Bloomberg.

The pharmacy discovered an impurity called dimethylformamide, which is classified as a probable carcinogen by the World Health Organization.

The impurity was found in valsartan manufactured by five companies, including Novartis. The online pharmacy recommended a recall.

The FDA will evaluate Valisure's findings.

Dozens of forms of generic valsartan have been recalled since July 2018, after an impurity known as N-Nitrosodimethylamine was detected in a version of the drug.

Dimethylformamide is the fourth potential carcinogen to be found in generic versions of the heart pills.

More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers